Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Clinical Trials
36
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
13
36.1%
No Longer Available
3
8.3%
Terminated
15
41.7%
Unknown
1
2.8%
Withdrawn
4
11.1%
No approval data available
- The BIOMEDE trial enrolled 218 pediatric patients with diffuse intrinsic pontine glioma (DIPG) and failed to show superior overall survival for any experimental arm versus radiotherapy alone, yet provided crucial molecular insights for future trial design. - Mandatory tumor biopsy requirements generated comprehensive molecular profiling data, identifying that patients with EGFR pathway activation showed longer survival with erlotinib treatment compared to EGFR-negative patients. - The trial's biomarker architecture demonstrates that molecularly stratified populations are essential for DIPG drug development, as TP53 mutations emerged as the strongest prognostic factor with median survival of 8 months versus 15 months in wild-type tumors. - This study establishes mandatory molecular profiling as the new standard for pediatric CNS oncology trials, fundamentally changing how sponsors should design future DIPG development programs.
- Artios Pharma appointed three senior executives to strengthen late-stage development capabilities as the company advances its DNA Damage Response pipeline toward commercialization. - Roy W. Ware joins as Chief Manufacturing and Technology Officer, bringing over 20 years of experience in advancing first-in-class oncology programs through FDA approval. - The leadership team will support the advancement of alnodesertib into late-stage development and potential U.S. commercialization while executing Phase 2 studies for ART6043. - These appointments establish integrated capabilities across manufacturing, clinical operations, and medical affairs to accelerate delivery of potential first-in-class DDR medicines to cancer patients.
- Jazz Pharmaceuticals achieved record total revenues of $4.3 billion in 2025, representing 5% year-over-year growth and marking the company's 21st consecutive year of top-line growth. - The company plans to complete a supplemental biologics license application submission for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma in Q1 2026, with potential launch in the second half of 2026. - Xywav generated $1.7 billion in revenue with 12% year-over-year growth, while Epidiolex achieved blockbuster status with $1.1 billion in sales and 9% growth. - Jazz expects 2026 total revenues between $4.25 to $4.50 billion, driven by double-digit growth in epilepsy and oncology franchises.
- Altimmune has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025, bringing over 30 years of commercial experience in metabolic disease and hepatology. - Richardson's appointment comes as Altimmune prepares to initiate Phase 3 development of pemvidutide for MASH treatment, positioning the company for future commercial success. - The new CCO previously served as Chief Commercial Officer at Intercept Pharmaceuticals and held senior commercial roles at Sanofi, including Global Commercial Head of the GLP-1 program Lixisenatide. - Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed for multiple indications including MASH, Alcohol Use Disorder, and Alcohol-associated Liver Disease.
- The FDA has granted accelerated approval to dordaviprone (Modeyso) for adult and pediatric patients aged 1 year and older with H3 K27M-mutated diffuse midline glioma following disease progression after prior therapy. - This represents the first FDA approval of a systemic therapy specifically for H3 K27M-mutant diffuse midline glioma, addressing a significant unmet medical need. - Clinical trials demonstrated a 22% overall response rate with a median duration of response of 10.3 months among 50 patients with recurrent disease. - The protease activator received multiple FDA designations including Priority Review, Orphan Drug, Rare Pediatric Disease, and Fast Track status.
- Jazz Pharmaceuticals' Board of Directors unanimously selected Renee Gala as President and CEO, effective August 11, 2025, succeeding co-founder Bruce Cozadd who will remain as Board Chairperson. - Gala's leadership has driven Jazz's transformation with nearly 90% revenue growth and diversified portfolio expansion, positioning the company for sustainable growth with a robust oncology and neuroscience pipeline. - The leadership transition comes as Jazz pursues ambitious growth targets including a $5 billion revenue goal by 2025, with key regulatory milestones and clinical readouts expected in the coming months.
- DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases. - Recent clinical milestones include Kamada's post-marketing research initiative for CYTOGAM, ACTG's encouraging HIV-CMV study results, and Fortress Biotech's Phase 2 trial initiation for Triplex vaccine. - The CMV pipeline encompasses diverse therapeutic approaches including mRNA vaccines, T-cell therapies, immune globulins, and antiviral compounds from companies like Moderna, Merck Sharp & Dohme, and Chimerix. - Market growth is driven by increasing CMV prevalence and research activities, though high treatment costs and healthcare infrastructure limitations present ongoing challenges.
• Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively. • The company submitted a supplemental New Drug Application for Zepzelca in combination with atezolizumab as maintenance therapy for first-line extensive-stage small cell lung cancer, based on promising Phase 3 trial results. • Jazz completed the acquisition of Chimerix, adding dordaviprone to its late-stage pipeline for H3 K27M-mutant diffuse glioma, with an FDA PDUFA target date of August 18, 2025.
• DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer. • Several promising candidates are advancing through clinical trials, including GlycoMimetics' uproleselan in Phase III, BioSight's aspacytarabine (BST-236) in Phase II, and novel approaches like Senti Biosciences' logic-gated CAR-NK cell therapy. • Recent developments include Moleculin Biotech's Phase III MIRACLE trial for annamycin, Qurient's adrixetinib IND approval, and Rigel Pharmaceuticals' trial of REZLIDHIA in combination therapy for IDH1-mutated AML.
- Jazz Pharmaceuticals has announced the strategic acquisition of Chimerix, expanding its portfolio with a promising late-stage drug candidate. - The acquisition positions Jazz to strengthen its presence in the pharmaceutical market, with potential near-term approval catalysts on the horizon. - The deal demonstrates Jazz's continued commitment to growth through strategic acquisitions in the specialty pharmaceutical space.
